Vistagen Therapeutics, Inc. quarterly report, Q3 FY2009

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2009, for Excaliber Enterprises, Ltd. (Note: The input metadata referenced "Vistagen Therapeutics," but the filing text explicitly identifies the registrant as Excaliber Enterprises, Ltd.). The company is a Nevada corporation classified as a development stage company and a shell company. Its stated business is selling specialty gift baskets to health care professionals, organizations, patients, and real estate agents. As of the reporting date, the company had generated no revenue since its inception in October 2005.

Key Financial Metrics

MetricThree Months Ended 9/30/09Nine Months Ended 9/30/09Inception to 9/30/09
Revenue$0$0$0
Total Expenses$1,293$20,561$47,162
Net Loss$(1,293)$(20,591)$(47,252)
Cash Balance (Ending)$3,042$3,042$3,042
Operating Cash FlowN/A$(20,270)$(39,709)
Current Liabilities$2,686$2,686$2,686
Debt$500 (Related Party)$500 (Related Party)$500 (Related Party)
Shares Outstanding5,848,7075,848,7075,848,707

Note: The company has no revenue, resulting in no gross or net margins. Liquidity is critically low with cash of $3,042 against current liabilities of $2,686.

Material Changes vs. Prior Period

  • Expense Increase: Total expenses for the nine months ended September 30, 2009, were $20,561, a significant increase from $3,409 in the comparable 2008 period. This increase is attributed to the resumption of operations following a private equity offering closed in November 2008.
  • Cash Position: Cash decreased from $21,812 at December 31, 2008, to $3,042 at September 30, 2009, due to operating losses and fixed asset purchases.
  • Financing: The company secured a $20,000 Revolving Line of Credit on August 19, 2009, though no funds had been drawn as of the reporting date.

Outlook, Risks, and Management Commentary

  • Going Concern: Management and auditors have expressed substantial doubt about the company's ability to continue as a going concern. The company has incurred cumulative losses of $47,252 and has no revenue. Continued operations depend entirely on securing additional equity or debt financing.
  • Plan of Operation: Management intends to use the $20,000 line of credit to improve its website (adding e-commerce functionality), launch web advertising campaigns (Google, Bing, Yahoo), and fund direct sales materials. Budget allocations include up to $6,000 for the website, $10,000 for advertising, and $2,000 for sales materials.
  • Internal Controls: Management identified a material weakness in internal controls due to the lack of a functioning audit committee and a lack of independent outside directors. Remediation plans include establishing a formal audit committee and recruiting outside directors.
  • Risks: Key risks include the inability to generate revenue, failure to secure additional capital, and the potential for investors to lose their entire investment if the business fails.

Investor Verification Checklist

  • Capital Adequacy: Verify if the company has secured the additional financing required to survive the next 12 months, given the $3,042 cash balance and $2,686 in current liabilities.
  • Line of Credit Utilization: Confirm whether the company has drawn any funds from the $20,000 revolving line of credit secured in August 2009.
  • Revenue Generation: Monitor for any actual sales or revenue recognition, as the company has had zero revenue since inception in 2005.
  • Internal Control Remediation: Track progress on appointing independent directors and forming an audit committee to address the identified material weakness.
  • Related Party Transactions: Review the $500 related-party note payable and the history of stock issuances for services to ensure fair valuation and disclosure.